5-oxoproline glutathione Pyroglutamic Acidosis • LITFL • CCC Acid-base Acquired 5-oxoproline acidemia successfully treated

These processes converge on circadian rhythm dysfunction, which is further reinforced by oxidative stress, increased reactive oxygen species (ROS) production, and alterations in circadian clock gene expression

Morning: Cleanse Toner Serum/Ampoule Cream Sunscreen

C.BramsM

Mechanism of Action Tirzepatide: Dual incretin (GIP + GLP-1) enhanced metabolic impact Wegovy: GLP-1 receptor agonist now with higher receptor engagement Weight Loss Outcomes Tirzepatide: ~22% weight reduction in trials Wegovy 7.2 mg: ~2021% weight reduction The efficacy gap is narrowing significantly Cardiometabolic Profile Wegovy: Strong, established cardiovascular outcome data Tirzepatide: Superior glycemic control and insulin sensitivity Safety & Tolerability Both therapies show dose-dependent GI side effects Overall safety profiles remain comparable The Big Picture We are witnessing a shift from: Single-hormone optimization (high-dose semaglutide) to Multi-hormone targeting (tirzepatide) Conclusion While Wegovy is rapidly closing the efficacy gap with dose escalation, Tirzepatide continues to lead as a next-generation metabolic therapy